Alpha-Naphthoflavone

Name: Alpha-Naphthoflavone
Brand: MedChemExpress
SKU: HY-125833
Rating: 5.0 (6 reviews)

Cat. No.: HY-125833 Purity: 98.54%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Alpha-Naphthoflavone is an orally active flavonoid that is a potent, competitive inhibitor of aromatasearomatase. IC 50 and K I value were 0.5 and 0.2 microns. Alpha-Naphthoflavone can inhibit cell proliferation and induce apoptosis.

For research use only. We do not sell to patients.

Alpha-Naphthoflavone Chemical Structure

CAS No. : 604-59-1

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 80	In-stock	Estimated Time of Arrival: December 31
20 mg	USD 140	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 210	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 320	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

6 Publications Citing Use of MCE Alpha-Naphthoflavone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms

CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A4 CYP17A1

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Aromatase

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	11.3 μM Compound: 14	Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay	[PMID: 23851114]
A2780 ADR	IC₅₀	24.6 μM Compound: 14	Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay	[PMID: 23851114]
HEK293	IC₅₀	> 10 μM Compound: ANF	Inhibition of human CYP1A1 expressed in HEK293 cells using fluorogenic substrate 7-ethoxyresorufin as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay Inhibition of human CYP1A1 expressed in HEK293 cells using fluorogenic substrate 7-ethoxyresorufin as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	[PMID: 28711350]
HEK293	IC₅₀	> 10 μM Compound: ANF	Inhibition of human CYP1B1 expressed in HEK293 cells using fluorogenic 7-ethoxyresorufin as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay Inhibition of human CYP1B1 expressed in HEK293 cells using fluorogenic 7-ethoxyresorufin as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	[PMID: 28711350]
HEK293	IC₅₀	> 10000 nM Compound: 3; ANF	Inhibition of recombinant human liver CYP1A1 expressed in HEK293 cells using 7-ethoxyresorufin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by EROD assay Inhibition of recombinant human liver CYP1A1 expressed in HEK293 cells using 7-ethoxyresorufin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by EROD assay	[PMID: 28259840]
HEK293	IC₅₀	> 10000 nM Compound: 3; ANF	Inhibition of recombinant human liver CYP1B1 expressed in HEK293 cells using 7-ethoxyresorufin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by EROD assay Inhibition of recombinant human liver CYP1B1 expressed in HEK293 cells using 7-ethoxyresorufin as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by EROD assay	[PMID: 28259840]
HEK293	IC₅₀	> 50 μM Compound: 4; ANF	Inhibition of human liver CYP1B1 expressed in HEK293 cells using 7-ethoxyresorufin as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay Inhibition of human liver CYP1B1 expressed in HEK293 cells using 7-ethoxyresorufin as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay	[PMID: 28222316]
HEK293	IC₅₀	> 50 μM Compound: 4; ANF	Inhibition of human liver CYP1B1 expressed in HEK293 cells using CEC as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay Inhibition of human liver CYP1B1 expressed in HEK293 cells using CEC as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay	[PMID: 28222316]
HEK293	EC₅₀	40 μM Compound: 4; ANF	Inhibition of human CYP1B1 expressed in HEK293 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 0.016 uM by MTT assay (Rvb = 61 +/- 8 uM) Inhibition of human CYP1B1 expressed in HEK293 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 0.016 uM by MTT assay (Rvb = 61 +/- 8 uM)	[PMID: 28222316]
HepG2	IC₅₀	0.32 μM Compound: alpha-naphthoflavone	Inhibition of TCDD-induced EROD activity in human HepG2 cells after 24 hrs Inhibition of TCDD-induced EROD activity in human HepG2 cells after 24 hrs	[PMID: 15787451]
MCF7	IC₅₀	> 100 μM Compound: ANF	Cytotoxicity against drug-resistant TCCD-induced human MCF7 cells overexpressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against drug-resistant TCCD-induced human MCF7 cells overexpressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31803401]
MCF7	IC₅₀	110.6 μM Compound: ANF	Inhibition of CYP1B1 in TCDD-stimulated human MCF7 cells assessed as inhibition of anticancer drug resistance by measuring docetaxel cytotoxic IC50 at 5 uM after 48 hrs by MTT assay (Rvb = 139.8 +/- 11.5 microM) Inhibition of CYP1B1 in TCDD-stimulated human MCF7 cells assessed as inhibition of anticancer drug resistance by measuring docetaxel cytotoxic IC50 at 5 uM after 48 hrs by MTT assay (Rvb = 139.8 +/- 11.5 microM)	[PMID: 25799264]
MCF7	IC₅₀	80.7 μM Compound: ANF	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31803401]
MCF7	IC₅₀	98.2 μM Compound: ANF	Inhibition of CYP1B1 in TCDD-stimulated human MCF7 cells assessed as inhibition of anticancer drug resistance by measuring docetaxel cytotoxic IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 139.8 +/- 11.5 microM) Inhibition of CYP1B1 in TCDD-stimulated human MCF7 cells assessed as inhibition of anticancer drug resistance by measuring docetaxel cytotoxic IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 139.8 +/- 11.5 microM)	[PMID: 25799264]
MDA-MB-231	IC₅₀	> 100 μM Compound: ANF	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31803401]
MDCK-II	IC₅₀	1.31 μM Compound: 14	Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay	[PMID: 23851114]
MDCK-II	IC₅₀	1.4 μM Compound: 14	Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry	[PMID: 23851114]

In Vitro

Alpha-Naphthoflavone (0.01-100 μM, 5 min) induces vascular relaxation by inducing extracellular calcium inflow and NO formation^[2].
Alpha-Naphthoflavone (0.01-100 μM, 48 h) can inhibit HeLa cell proliferation, block the G1/S phase, and increase p53 level and apoptosis^[3].
Alpha-Naphthoflavone (5, 10, 20, 40 μM, 24 h) can protect HepG2 hepatocytes treated with oleic acid (OA)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:	HeLa
Concentration:	0.01, 1, 10, 100 μM
Incubation Time:	6 days
Result:	Decreased cell proliferation in a dose-dependent manner with IC₅₀ value of 36.81 μM.

Apoptosis Analysis^[3]

Cell Line:	HeLa
Concentration:	50 μM
Incubation Time:	12, 24, 36 h
Result:	Induced a mild but significant apoptosis rate.

Western Blot Analysis^[3]

Cell Line:	HeLa
Concentration:	50 μM
Incubation Time:	12, 24, 36 h
Result:	Increased the level of p53 at 12 h.

In Vivo

Alpha-Naphthoflavone (80, 160 mg/kg/day, gavage for 4 weeks) has protective effects on NAFLD mice induced by high-fat diet (HFD)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HFD-induced mice model^[4]
Dosage:	80, 160 mg/kg
Administration:	i.g.
Result:	Decreased the levels of AST, TG and TC.

Molecular Weight

272.30

Formula

C₁₉H₁₂O₂

CAS No.

604-59-1

Appearance

Solid

Color

White to light yellow

SMILES

O=C1C=C(C2=CC=CC=C2)OC3=C1C=CC4=CC=CC=C43

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (91.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.6724 mL	18.3621 mL	36.7242 mL
5 mM	0.7345 mL	3.6724 mL	7.3448 mL
10 mM	0.3672 mL	1.8362 mL	3.6724 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.54%

Select Batch:

Data Sheet (283 KB) SDS (392 KB)

COA (254 KB) HNMR (253 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. Campbell DR, et al. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J Steroid Biochem Mol Biol. 1993 Sep;46(3):381-8. [Content Brief]

[2]. Cheng YW, et al. Alpha-naphthoflavone induces vasorelaxation through the induction of extracellular calcium influx and NO formation in endothelium. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):377-85. [Content Brief]

[3]. Flores-Pérez A, et al. Apoptosis induction and inhibition of HeLa cell proliferation by alpha-naphthoflavone and resveratrol are aryl hydrocarbon receptor-independent. Chem Biol Interact. 2018 Feb 1;281:98-105. [Content Brief]

[4]. Xia H, et al. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice. Biomed Pharmacother. 2019 Oct;118:109287. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.6724 mL	18.3621 mL	36.7242 mL	91.8105 mL
	5 mM	0.7345 mL	3.6724 mL	7.3448 mL	18.3621 mL
	10 mM	0.3672 mL	1.8362 mL	3.6724 mL	9.1811 mL
	15 mM	0.2448 mL	1.2241 mL	2.4483 mL	6.1207 mL
	20 mM	0.1836 mL	0.9181 mL	1.8362 mL	4.5905 mL
	25 mM	0.1469 mL	0.7345 mL	1.4690 mL	3.6724 mL
	30 mM	0.1224 mL	0.6121 mL	1.2241 mL	3.0604 mL
	40 mM	0.0918 mL	0.4591 mL	0.9181 mL	2.2953 mL
	50 mM	0.0734 mL	0.3672 mL	0.7345 mL	1.8362 mL
	60 mM	0.0612 mL	0.3060 mL	0.6121 mL	1.5302 mL
	80 mM	0.0459 mL	0.2295 mL	0.4591 mL	1.1476 mL